- 专利标题: Unique dual-action therapeutics
-
申请号: US15365088申请日: 2016-11-30
-
公开(公告)号: US10570161B2公开(公告)日: 2020-02-25
- 发明人: Jeffrey D. Laskin , Diane E. Heck , Mou-Tuan Huang , Karine Fabio , Carl J. Lacey , Sherri C. Young , Pramod Mohanta , Christophe Guillon , Ned D. Heindel
- 申请人: Rutgers, The State University of New Jersey , Lehigh University
- 申请人地址: US NJ New Brunswick US PA Bethlehem
- 专利权人: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY,LEHIGH UNIVERSITY
- 当前专利权人: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY,LEHIGH UNIVERSITY
- 当前专利权人地址: US NJ New Brunswick US PA Bethlehem
- 代理机构: Fox Rothschild LLP
- 主分类号: C07F7/08
- IPC分类号: C07F7/08 ; A61K31/405 ; A61K31/196 ; A61K31/19 ; A61K47/55 ; A61K47/54 ; A61K9/00 ; A61K31/192 ; C07C69/96 ; C07C229/42 ; C07C209/28 ; C07D209/28
摘要:
A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X=C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.
公开/授权文献
- US20170143836A1 UNIQUE DUAL-ACTION THERAPEUTICS 公开/授权日:2017-05-25
信息查询